About
Universal Flu Vaccine
Areas of Focus
Categories
Vaccine
Team (23)
Alexandre Le Vert
Executive Chairman & Co-Founder
Osivax
team_memberboard_chairfounder
Bernard Fritzell
Member of the clinical Advisory Board
Osivax
team_member
Chris Martin
Chairman of the Board of Tokamak Energy Ltd
Osivax
team_memberboard_chair
Christian Pradeyrol
Executive Chairman and founder of Pradeyrol Développement
Osivax
team_memberfounderboard_chair
Dr Bernard Fritzell
Member of the clinical Advisory Board
Osivax
team_member
Dr Chris Martin
Chairman of the Board of Tokamak Energy Ltd
Osivax
team_memberboard_chair
Clinical Trials (10)
View allTotal Trials
10
As Lead Sponsor
10
As Collaborator
0
Total Enrollment
4,469
By Phase
PHASE2: 6PHASE1: 2
By Status
COMPLETED: 9NOT_YET_RECRUITING: 1
Clinical Trials Pipeline10 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
Today
Hover over trial bars to see details
Recent Trials
NCT05569239Lead Sponsor
Efficacy, Immunogenicity and Safety of OVX836 Influenza Vaccine 480μg
PHASE2Not yet recruiting
2,850 participants
Started: Sep 8, 2025 · Completed: May 29, 2026
NCT06779981Lead Sponsor
A Prospective Epidemiological Study Evaluating Occurrences of Influenza-like Illness
N/ACompleted
119 participants
Started: Dec 13, 2024 · Completed: Jun 19, 2025
NCT06582277Lead Sponsor
Safety and Immunogenicity of Two Dose Levels of OVX836 Influenza Vaccine as a Booster on Participants Previously Administered With OVX836
PHASE2Completed
117 participants
Started: Oct 22, 2024 · Completed: Jun 2, 2025
NCT06128382Lead Sponsor
First-in-human Study to Evaluate the Safety and Immunogenicity of Three Dose Levels of the OVX033 Coronavirus Vaccine Candidate in Healthy Volunteers
PHASE1Completed
48 participants
Started: Jan 8, 2024 · Completed: Nov 29, 2024
NCT05734040Lead Sponsor
Immunogenicity and Safety of the Concomitant Administration of OVX836 Influenza Vaccine, Quadrivalent Inactivated Influenza Vaccines and Placebo in Healthy Subjects.
PHASE2Completed
478 participants
Started: May 10, 2023 · Completed: Jan 15, 2024
Locations (1)
Headquarters
Lyon, France
Map
Loading map...